Carbidopa
25 mg · Tablet
- Prescription only
- Active substance
- Carbidopa
- Made by
- Zydus Lifesciences Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
This information is not included in the verified source. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Carbidopa). It describes the substance, not this exact product.
Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum.
Administration of dopamine is ineffective in the treatment of Parkinson's disease apparently because it does not cross the blood-brain barrier.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-12-17
Safety of the active substance
From the US prescribing label for the same active substance (Carbidopa). It describes the substance, not this exact product.
- Carbidopa is contraindicated in patients with known hypersensitivity to any component of this drug.
- Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa.
- These inhibitors must be discontinued at least two weeks prior to initiating therapy with levodopa.
- Carbidopa-levodopa, or levodopa may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g., selegiline HCl) (see PRECAUTIONS, Drug Interactions ).
The most common adverse reactions have included dyskinesias such as choreiform, dystonic, and other involuntary movements, and nausea.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Details
| Made by | Zydus Lifesciences Limited |
|---|---|
| Active substance | Carbidopa |
| Strength | 25 mg |
| Form | Tablet |
| Route | Oral |
| Packs | 100 TABLET in 1 BOTTLE |
| NDC | 70771-1355 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
8 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Tablet8 products
25 mg8
25 mg · 8 companies
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.